| Ambrx Biopharma, Inc. |
President and CEO, Director |
Common Stock |
0 |
$0 |
$9.82 |
07 Mar 2024 |
Direct |
| Ambrx Biopharma, Inc. |
President and CEO, Director |
Restricted Stock Units |
0 |
$0 |
$9.82 |
07 Mar 2024 |
Direct |
| DiaMedica Therapeutics Inc. |
Director |
Voting Common Shares, no par value per share |
0 |
$0 |
$3.65 |
20 Feb 2025 |
Direct |
| ZyVersa Therapeutics, Inc. |
Director, 10%+ Owner |
Common Stock |
1,377,598 |
|
|
12 Dec 2022 |
Indirect |
| Ambrx Biopharma Inc. |
President and CEO, Director |
Stock Option (right to buy) |
1,216,500 |
|
|
05 Jul 2023 |
Direct |
| ZyVersa Therapeutics, Inc. |
Director, 10%+ Owner |
Warrant (right to buy) |
177,204 |
|
|
12 Dec 2022 |
Indirect |
| DiaMedica Therapeutics Inc. |
Director |
Stock Option (right to buy) |
64,242 |
|
|
20 Feb 2025 |
Direct |
| ZyVersa Therapeutics, Inc. |
Director, 10%+ Owner |
Series A Convertible Preferred Stock |
1,750 |
|
|
12 Dec 2022 |
Direct |
| ZyVersa Therapeutics, Inc. |
Director, 10%+ Owner |
Warrant (right to buy) |
1,750 |
|
|
12 Dec 2022 |
Direct |
| SEELOS THERAPEUTICS, INC. |
Director |
Stock Option (right to buy) |
1,666 |
|
|
04 Jan 2024 |
Direct |
| Ambrx Biopharma, Inc. |
President and CEO, Director |
Option to Purchase Common Stock |
0 |
|
|
07 Mar 2024 |
Direct |